KDM6A suppresses proliferation and epithelial-mesenchymal transition in prostate cancer cells.
The findings reveal the functional role of KDM6A in CRPC and suggest its potential utility in exploring novel therapeutic strategies for CRPC.
We have 3 of 7 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
The findings reveal the functional role of KDM6A in CRPC and suggest its potential utility in exploring novel therapeutic strategies for CRPC.
Resistance to androgen receptor (AR)-targeted therapies remains a major clinical challenge in advanced prostate cancer. Here we identify follistatin (FST), TGFβ superfamily antagonist, as a key driver of AR-independence and treatment resistance. During anti-AR therapy, cancer cells progressively lose the positive feedb...
A pH-responsive nanocomposite engineered by functionalizing brain-metastatic tumor cell-derived exosomes with RGD peptides for targeted co-delivery of verteporfin and αPD-L1 successfully remodels the intracranial immunosuppressive microenvironment and triggers potent systemic anti-tumor immunity.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.